Scott M Schuetze

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. doi request reprint Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor
    Scott M Schuetze
    University of Michigan, Ann Arbor, Michigan
    Cancer . 2016
  2. doi request reprint Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma
    Scott M Schuetze
    Division of Hematology Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI 48109 5848, United States
    Eur J Cancer 48:1347-53. 2012
  3. ncbi request reprint Adjuvant therapy for soft tissue sarcoma
    Scott M Schuetze
    Department of Medicine, Division of Hematology Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA
    J Natl Compr Canc Netw 3:207-13. 2005
  4. ncbi request reprint Chemotherapy in the management of osteosarcoma and Ewing's sarcoma
    Scott M Schuetze
    Department of Medicine, Division of Hematology Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 0848, USA
    J Natl Compr Canc Netw 5:449-55. 2007
  5. ncbi request reprint Utility of positron emission tomography in sarcomas
    Scott M Schuetze
    Division of Hematology Oncology, Department of Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 0848, USA
    Curr Opin Oncol 18:369-73. 2006
  6. ncbi request reprint Imaging and response in soft tissue sarcomas
    Scott M Schuetze
    Division of Hematology Oncology, Box 0848, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109 0848, USA
    Hematol Oncol Clin North Am 19:471-87, vi. 2005
  7. ncbi request reprint Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy
    Scott M Schuetze
    Department of Medicine, University of Washington Medical Center, Seattle, Washington, USA
    Cancer 103:339-48. 2005
  8. doi request reprint Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial
    Rashmi Chugh
    Department of Internal Medicine, University of Michigan, Ann Arbor, 48109 5843, USA
    Clin Cancer Res 16:4884-91. 2010
  9. pmc [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults
    Douglas S Hawkins
    Department of Pediatrics, Seattle Children s Hospital, and Department of Orthopedics, University of Washington, Seattle, Washington 98105 0371, USA
    Cancer 115:3519-25. 2009
  10. ncbi request reprint [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors
    Douglas S Hawkins
    Children s Hospital and Regional Medical Center, 4800 Sandpoint Way, Mailstop B 6553, Seattle, WA 98105 0371, USA
    J Clin Oncol 23:8828-34. 2005

Detail Information

Publications36

  1. doi request reprint Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor
    Scott M Schuetze
    University of Michigan, Ann Arbor, Michigan
    Cancer . 2016
    ..Alveolar soft part sarcoma (ASPS), chondrosarcoma (CS), chordoma, epithelioid sarcoma, and solitary fibrous tumor (SFT) are malignant tumors that are relatively resistant to chemotherapy and for which more effective drug therapy is needed...
  2. doi request reprint Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma
    Scott M Schuetze
    Division of Hematology Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI 48109 5848, United States
    Eur J Cancer 48:1347-53. 2012
    ..The combination of sirolimus and cyclophosphamide demonstrated synergistic anti-sarcoma activity in preclinical models; therefore, we conducted a phase II trial of sirolimus and cyclophosphamide in patients with advanced sarcoma...
  3. ncbi request reprint Adjuvant therapy for soft tissue sarcoma
    Scott M Schuetze
    Department of Medicine, Division of Hematology Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA
    J Natl Compr Canc Netw 3:207-13. 2005
    ....
  4. ncbi request reprint Chemotherapy in the management of osteosarcoma and Ewing's sarcoma
    Scott M Schuetze
    Department of Medicine, Division of Hematology Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 0848, USA
    J Natl Compr Canc Netw 5:449-55. 2007
    ..Patient participation in clinical trials of novel therapies for Ewing's sarcoma and osteosarcoma should be strongly encouraged...
  5. ncbi request reprint Utility of positron emission tomography in sarcomas
    Scott M Schuetze
    Division of Hematology Oncology, Department of Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 0848, USA
    Curr Opin Oncol 18:369-73. 2006
    ..Recent developments in the use of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the clinical management of patients with suspected or diagnosed sarcomas are presented...
  6. ncbi request reprint Imaging and response in soft tissue sarcomas
    Scott M Schuetze
    Division of Hematology Oncology, Box 0848, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109 0848, USA
    Hematol Oncol Clin North Am 19:471-87, vi. 2005
    ..Functional imaging of soft tissue sarcomas may prove to be useful clinically, therefore further investigation is warranted...
  7. ncbi request reprint Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy
    Scott M Schuetze
    Department of Medicine, University of Washington Medical Center, Seattle, Washington, USA
    Cancer 103:339-48. 2005
    ..Serial FDG-PET scans were taken to determine the correlation between FDG uptake and patient outcomes in patients receiving multimodality treatment of extremity sarcomas...
  8. doi request reprint Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial
    Rashmi Chugh
    Department of Internal Medicine, University of Michigan, Ann Arbor, 48109 5843, USA
    Clin Cancer Res 16:4884-91. 2010
    ..Here, we report specifically on the outcome of patients with AF as well as evaluations undertaken to examine the mechanism of imatinib...
  9. pmc [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults
    Douglas S Hawkins
    Department of Pediatrics, Seattle Children s Hospital, and Department of Orthopedics, University of Washington, Seattle, Washington 98105 0371, USA
    Cancer 115:3519-25. 2009
    ..To determine the prognostic value of FDG-PET response for progression-free survival (PFS) in osteosarcoma, the authors of this report reviewed the University of Washington Medical Center experience...
  10. ncbi request reprint [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors
    Douglas S Hawkins
    Children s Hospital and Regional Medical Center, 4800 Sandpoint Way, Mailstop B 6553, Seattle, WA 98105 0371, USA
    J Clin Oncol 23:8828-34. 2005
    ..To determine the prognostic value of FDG PET response for progression-free survival (PFS) in ESFTs, we reviewed the University of Washington Medical Center experience...
  11. doi request reprint SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma
    Scott M Schuetze
    Division of Hematology Oncology, Department of Medicine, University of Michigan, Ann Arbor, Michigan
    Cancer 122:868-74. 2016
    ..Dasatinib exhibited activity in preclinical models of sarcoma. The Sarcoma Alliance for Research through Collaboration (SARC) conducted a multicenter, phase 2 trial of dasatinib in patients with advanced sarcoma...
  12. pmc Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial
    Gary K Schwartz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet Oncol 14:371-82. 2013
    ....
  13. doi request reprint Histologic alterations from neoadjuvant chemotherapy in high-grade extremity soft tissue sarcoma: clinicopathological correlation
    David R Lucas
    Department of Pathology, University of Michigan, Ann Arbor, Michigan 48109 0054, USA
    Oncologist 13:451-8. 2008
    ....
  14. doi request reprint Should patients with high-risk soft tissue sarcoma receive adjuvant chemotherapy?
    Scott M Schuetze
    University of Michigan, C342 Med Inn, SPC 5848, 1500 E Medical Center Drive, Ann Arbor, Michigan, 48109 5848, USA
    Oncologist 14:1003-12. 2009
    ..In the absence of conclusive results from an adequately powered, randomized, controlled clinical trial, the available data support the use of chemotherapy in the management of high-risk, localized, soft tissue sarcoma...
  15. ncbi request reprint Deep-seated, well differentiated lipomatous tumors of the chest wall and extremities: the role of cytogenetics in classification and prognostication
    Mikelle D Bassett
    Department of Anatomic Pathology, University of Washington Medical Center, Seattle, Washington 98195, USA
    Cancer 103:409-16. 2005
    ..The authors examined their single institutional experience and correlated their classification with clinical features and outcome...
  16. pmc SPARC expression in patients with high-risk localized soft tissue sarcoma treated on a randomized phase II trial of neo/adjuvant chemotherapy
    Elizabeth J Davis
    Division of Hematology Oncology, University of Michigan, 1500 E Medical Center Dr, Ann Arbor, MI, 48109, USA
    BMC Cancer 16:663. 2016
    ....
  17. doi request reprint Dermatofibrosarcoma protruberans treatment with platelet-derived growth factor receptor inhibitor: a review of clinical trial results
    Binu Malhotra
    Division of Hematology Oncology, Department of Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA
    Curr Opin Oncol 24:419-24. 2012
    ..Given its rarity, and paucity of randomized trials, the nuances of treatment are not widely understood. In this review we attempt to summarize the available data to guide treatment choices for physicians managing this disease...
  18. doi request reprint Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options
    Megan V Caram
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Michigan, USA
    J Surg Oncol 104:888-95. 2011
    ....
  19. doi request reprint Undifferentiated small round cell sarcoma with t(4;19)(q35;q13.1) CIC-DUX4 fusion: a novel highly aggressive soft tissue tumor with distinctive histopathology
    Eun Young Karen Choi
    Departments of Pathology Internal Medicine Orthopedic Surgery, University of Michigan, Ann Arbor, MI
    Am J Surg Pathol 37:1379-86. 2013
    ..8 months. CIC-DUX4 sarcoma represents a novel translocation-associated sarcoma with distinctive histopathologic features and rapid disease progression. ..
  20. pmc Bayesian decision theoretic two-stage design in phase II clinical trials with survival endpoint
    Lili Zhao
    Biostatistics Unit, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109, USA
    Stat Med 31:1804-20. 2012
    ..An example based on a recently conducted phase II sarcoma trial illustrates the method...
  21. doi request reprint Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors
    Hussein Tawbi
    Department of, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA
    Oncologist 13:459-66. 2008
    ..The present study extends that work to examine the expression of EGFR in MPNSTs and the characterization of potential targets of the EGFR tyrosine kinase domain...
  22. ncbi request reprint So-called "inflammatory leiomyosarcoma'': a series of 3 cases providing additional insights into a rare entity
    Anthony Chang
    Department of Pathology, University of Washington Medical Center, Seattle, WA 98195, USA
    Int J Surg Pathol 13:185-95. 2005
    ..In addition, 2 of the 3 cases developed distant metastases to the lungs, which suggests that these lesions may have a worse prognosis than previously believed...
  23. doi request reprint Selection of response criteria for clinical trials of sarcoma treatment
    Scott M Schuetze
    Department of Internal Medicine, Division of Hematology Oncology, 1500 E Medical Center Drive, C409 MIB, Ann Arbor, Michigan 48109 5843, USA
    Oncologist 13:32-40. 2008
    ....
  24. pmc Phase II study of sorafenib in patients with metastatic or recurrent sarcomas
    Robert G Maki
    Melanoma Sarcoma Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 909, New York, NY 10065, USA
    J Clin Oncol 27:3133-40. 2009
    ..Further evaluation of sorafenib in these and possibly other sarcoma subtypes appears warranted, presumably in combination with cytotoxic or kinase-specific agents...
  25. ncbi request reprint Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center New York, NY 10021, USA
    J Clin Oncol 25:2755-63. 2007
    ..To determine if the addition of docetaxel to gemcitabine improved clinical outcome of patients with metastatic soft tissue sarcomas, we compared a fixed dose rate infusion of gemcitabine versus a lower dose of gemcitabine with docetaxel...
  26. doi request reprint A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma
    Elizabeth J Davis
    Division of Hematology Oncology, University of Michigan, Ann Arbor, MI, United States
    Eur J Cancer 51:1794-802. 2015
    ..Gemcitabine and docetaxel (GD) has efficacy in metastatic STS and may be better tolerated. We conducted a study to compare toxicities and efficacies of these regimens...
  27. doi request reprint Ewing sarcoma of the kidney: case series and literature review of an often overlooked entity in the diagnosis of primary renal tumors
    R Grant Rowe
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109 5848, USA
    Urology 81:347-53. 2013
    ..To evaluate our own experience with primary Ewing sarcoma family tumors (ESFTs) of the kidney and to review cases of this in published reports...
  28. doi request reprint Histology-specific therapy for advanced soft tissue sarcoma and benign connective tissue tumors
    Ann W Silk
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Comprehensive Cancer Center, Ann Arbor, MI 48109, USA
    Curr Treat Options Oncol 13:285-98. 2012
    ..Participation in clinical trials, when available, is highly encouraged...
  29. ncbi request reprint Chordoma: the nonsarcoma primary bone tumor
    Rashmi Chugh
    Department of Internal Medicine, Division of Hematology Oncology, 24 Frank Lloyd Wright Drive, A3400, P O Box 483, Ann Arbor, Michigan 48106, USA
    Oncologist 12:1344-50. 2007
    ..Radiation therapy may also salvage some patients with local recurrence. One series reported a 2-year actuarial local control rate of 33% for patients treated with proton beam irradiation...
  30. ncbi request reprint Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans
    Brian P Rubin
    Department of Pathology, University of Washington Medical Center, Seattle, WA 98195, USA
    J Clin Oncol 20:3586-91. 2002
    ..We investigated the response of dermatofibrosarcoma protuberans to the tyrosine kinase inhibitor imatinib mesylate...
  31. pmc Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
    George D Demetri
    George D Demetri, Dana Farber Cancer Institute and Ludwig Center at Harvard, Boston, MA Margaret von Mehren, Fox Chase Cancer Center Arthur Staddon, University of Pennsylvania, Philadelphia Hussein Tawbi, University of Pittsburgh Cancer Institute, Pittsburgh, PA Robin L Jones, Seattle Cancer Care Alliance, Seattle, WA Martee L Hensley, Memorial Sloan Kettering Cancer Center Robert G Maki, Mount Sinai Medical Center, New York, NY Scott M Schuetze, University of Michigan, Ann Arbor, MI Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa City, IA Anthony Elias, University of Colorado Cancer Center, Aurora, CO Kristen Ganjoo, Stanford Hospital and Clinics, Stanford, CA Brian A Van Tine, Washington University in St Louis, St Louis, MO Alexander Spira, Virginia Cancer Specialists, Fairfax, VA Andrew Dean, St John of God Hospital Bendat Cancer Centre, Subiaco, Western Australia, Australia Nushmia Z Khokhar, Youn Choi Park,
    J Clin Oncol 34:786-93. 2016
    ....
  32. pmc Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival
    Vadim S Koshkin
    Vadim S Koshkin, Cleveland Clinic, Cleveland, OH Vanessa Bolejack, Cancer Research and Biostatistics, Seattle, WA Lawrence H Schwartz, Binsheng Zhao, Columbia University Medical Center, New York, NY Richard L Wahl, Mallinckrodt Institute of Radiology, Washington University in St Louis, St Louis, MO Rashmi Chugh, Scott M Schuetze, Laurence H Baker, University of Michigan Medical School Denise K Reinke, Sarcoma Alliance for Research Through Collaboration, Ann Arbor, MI Joo H O, The Catholic University of Korea Seoul St Mary s Hospital, Seoul, Republic of Korea and Shreyaskumar R Patel, The University of Texas MD Anderson Cancer Center, Houston, TX
    J Clin Oncol . 2016
    ..In this study, we aimed to compare the effectiveness of various radiologic response assessments for the prediction of overall survival (OS) within the same data set of patients with sarcoma...
  33. ncbi request reprint PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma
    Christopher W Ryan
    Christopher W Ryan, Oregon Health and Science University, Portland, OR Ofer Merimsky, Sackler School of Medicine, Tel Aviv, Israel Mark Agulnik, Northwestern University, Chicago, IL Jean Yves Blay, Centre Leon Berard, Lyon Antoine Italiano, Institut Bergonie, Bordeaux, France Scott M Schuetze, University of Michigan, Ann Arbor, MI Brian A Van Tine, Washington University in St Louis, St Louis, MO Robin L Jones and Ian R Judson, The Royal Marsden Hospital, London, United Kingdom Anthony D Elias, University of Colorado Denver, Aurora, CO Edwin Choy, Massachusetts General Hospital Jill Y Buck and Francois Lebel, ZIOPHARM Oncology, Boston, MA Thierry Alcindor, McGill University Health Center, Montreal, Quebec, Canada Vicki L Keedy, Vanderbilt University Medical Center, Nashville, TN Damon R Reed, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL Robert N Taub, Columbia University Medical Center Jonathan J Lewis, New York 10032
    J Clin Oncol . 2016
    ..The PICASSO III trial compared doxorubicin plus palifosfamide with doxorubicin plus placebo in patients who had received no prior systemic therapy for metastatic soft tissue sarcoma...
  34. ncbi request reprint Targeted therapy for dermatofibrosarcoma protuberans
    Thomas A Abrams
    Division of Hematology Oncology, Department of Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109 0848, USA
    Curr Oncol Rep 8:291-6. 2006
    ..Three phase II, multicenter clinical trials are open to further investigate the role of imatinib mesylate in DFSP...
  35. doi request reprint New targets for therapy of sarcoma
    John M Magenau
    Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
    Curr Opin Oncol 20:400-6. 2008
    ..Systemic treatment options for advanced sarcoma remain limited. Emerging trends exploring targeted therapy for the treatment of sarcoma are reviewed here...
  36. ncbi request reprint Fluorodeoxyglucose positron emission tomography scanning: basic principles and imaging of adult soft-tissue sarcomas
    Ernest U Conrad
    Department of Orthopaedics and Sports Medicine, University of Washington, Seattle 98195 6500, USA
    J Bone Joint Surg Am 86:98-104. 2004